SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

Kodu・Aktsiate loetelu・Pharming Group NV

P
Pharming Group NV

Suletud

1.418 4.19

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.357

Max

1.422

Põhinäitajad
By Trading Economics
Sissetulek	2.9M 7.5M
Müük	4.1M 97M
Aktsiakasum	0.009
Kasumimarginaal	7.758
Töötajad	404

Turustatistika
By TradingEconomics
Turukapital	-51M 946M
Eelmine avamishind	-2.77
Eelmine sulgemishind	1.418

Pharming Group NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. dets 2025, 20:41 UTC

Tulu

Suurimad hinnamuutused turgudel

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. dets 2025, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. dets 2025, 17:43 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. dets 2025, 17:01 UTC

Tulu

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. dets 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. dets 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. dets 2025, 21:37 UTC

Tulu

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. dets 2025, 21:36 UTC

Tulu

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. dets 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. dets 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. dets 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. dets 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. dets 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. dets 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. dets 2025, 16:33 UTC

Market Talk

Tulu

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pharming Group NV Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Pharming Group NV aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.